[{"data":1,"prerenderedAt":350},["ShallowReactive",2],{"content-route-/en/tools/candida-claim-clinician-questions":3},{"state":4,"owner":4,"route":5,"locale":6,"template":7,"content":15,"projection":127,"alternates":341},"target","/en/tools/candida-claim-clinician-questions","en-US",{"kind":8,"family":9,"sectionKeys":10},"tool","guidance",[11,12,13,14],"instructions","worksheet","privacy","sources",{"kind":8,"title":16,"description":17,"firstPublished":18,"evidenceAsOf":18,"lastUpdated":18,"changeNote":19,"tool":20,"relations":64,"body":94},"Questions for a clinician about a Candida claim","Prepare the exact claim, what has and has not been established, alternative explanations, test limitations, stop or pivot rules, and next questions without treating the worksheet as confirmation.","2026-07-15","Complete initial draft based on the Pathway B testing, claim-boundary, and US authority packs.",{"purpose":21,"notToInfer":22,"instructions":23,"privacy":24,"fields":25},"Help you turn a Candida-related explanation, test, or treatment claim into specific questions for a clinician, including what is known, what remains uncertain, what else should be considered, and when the current approach should stop or change.","This worksheet does not confirm Candida as the cause, diagnose a condition, estimate likelihood, validate a test or treatment, interpret a result, score symptoms, or recommend what to take or stop. A symptom pattern, test result, treatment response, or worsening does not by itself establish the explanation.","Use the claimant's exact words where possible and keep reported facts separate from assumptions. Mark unknowns openly, bring original reports and product labels if you choose, and use the completed sheet to ask a clinician what each finding can establish and what would change the plan. Do not use the worksheet to delay urgent help or to change prescribed care on your own.","Entries stay only in this open document. They are not submitted, uploaded, analyzed, scored, saved, placed in local or session storage or cookies, or included in analytics. Browser-entered values exist only in the current document and disappear when you navigate away, reload, or close the page.",[26,31,36,40,44,48,52,56,60],{"key":27,"label":28,"inputKind":29,"helpText":30},"discussion-date","Discussion date","date","Leave blank if no appointment is scheduled yet.",{"key":32,"label":33,"inputKind":34,"helpText":35},"exact-claim","The exact Candida claim I want to discuss","textarea","Copy the wording and where it came from; avoid replacing it with a broader conclusion.",{"key":37,"label":38,"inputKind":34,"helpText":39},"established","What has actually been established so far","Record any clinician-stated diagnosis, examination, test method, specimen, result, and applicable body site in the words used in the report or visit.",{"key":41,"label":42,"inputKind":34,"helpText":43},"not-established","What has not been established or remains uncertain","List assumptions, missing information, and points where you are unsure what a symptom, detection, or result means.",{"key":45,"label":46,"inputKind":34,"helpText":47},"alternatives","Other explanations or evaluations to ask about","Ask which alternatives fit the main concerns and how they would be assessed; this field does not rank possible causes.",{"key":49,"label":50,"inputKind":34,"helpText":51},"testing-limitations","Questions about the test and its limitations","Ask what condition and population the test is intended for, what it measures, its validation and limitations, and how either result would change care.",{"key":53,"label":54,"inputKind":34,"helpText":55},"current-actions","Current treatments, supplements, diets, or other actions to review","Copy exact names, ingredients, doses, dates, and changes or unwanted effects when known; do not use this field to choose an intervention.",{"key":57,"label":58,"inputKind":34,"helpText":59},"stop-pivot","Stop, reassess, and urgent-help rules to agree","Ask which observable changes mean stop an action, seek reassessment, change the working explanation, or get prompt or emergency help.",{"key":61,"label":62,"inputKind":34,"helpText":63},"next-questions","Next questions and decisions for the clinician","Note what should be clarified now, what information is still needed, and what outcome or finding would change the next step.",[65,69,73,76,80,83,86,90],{"group":66,"route":67,"label":68},"parent","/en/tools","Tools",{"group":70,"route":71,"label":72},"differential","/en/symptoms-conditions/candida-terms","Candida terminology",{"group":70,"route":74,"label":75},"/en/symptoms-conditions/sifo","SIFO orientation",{"group":77,"route":78,"label":79},"treatment","/en/treatments-evidence/candida-overgrowth-claim","The broad Candida overgrowth claim",{"group":77,"route":81,"label":82},"/en/treatments-evidence/candida-tests","Candida tests",{"group":77,"route":84,"label":85},"/en/treatments-evidence/candida-die-off","Candida die-off",{"group":87,"route":88,"label":89},"evidence","/en/research/evidence/broad-candida-claims","Broad Candida claims evidence map",{"group":91,"route":92,"label":93},"safety","/en/urgent-help","Urgent help",{"type":95,"value":96,"toc":123},"minimark",[97,105,111,117],[98,99,101],"content-section",{"section-key":11,"title":100},"Use the claim as a question, not a conclusion",[102,103,104],"p",{},"Write down the exact claim and separate reported diagnoses, test methods, results, and observed changes from your interpretation. Bring the original report or product label if it is relevant. The aim is a precise clinical conversation, not confirmation of a self-diagnosis.",[98,106,108],{"section-key":12,"title":107},"What the worksheet covers",[102,109,110],{},"The fields provide date space and organize the exact claim, established and uncertain points, alternatives, test limitations, current actions, stop or pivot rules, and next questions. They do not calculate, rank, diagnose, or interpret entries.",[98,112,114],{"section-key":13,"title":113},"Privacy boundary",[102,115,116],{},"Nothing entered is sent or saved. Browser-entered values exist only in the current document and disappear when you navigate away, reload, or close the page.",[98,118,120],{"section-key":14,"title":119},"Method and sources",[102,121,122],{},"The prompts are limited to the conversation-preparation, testing-boundary, claim-boundary, and worsening-safety conclusions in the cited canonical records. Linked draft pages supply navigation labels only. The evidence methodology explains how Candipedia selects, checks, and updates sources.",{"title":124,"searchDepth":125,"depth":125,"links":126},"",2,[],{"sources":128,"claims":201,"safety":301},[129,137,141,147,155,162,168,176,183,188,194],{"sourceId":130,"title":131,"canonicalId":132,"canonicalUrl":133,"publisher":134,"sourceType":135,"publicationDate":136,"lastChecked":18},"cdc-candidiasis-basics-2024","Candidiasis Basics",null,"https://www.cdc.gov/candidiasis/about/index.html","US Centers for Disease Control and Prevention","regulator","2024-04-24",{"sourceId":138,"title":139,"canonicalId":132,"canonicalUrl":140,"publisher":134,"sourceType":135,"publicationDate":136,"lastChecked":18},"cdc-candidiasis-testing-2024","Testing and Diagnosis for Candidiasis","https://www.cdc.gov/candidiasis/testing/index.html",{"sourceId":142,"title":143,"canonicalId":132,"canonicalUrl":144,"publisher":145,"sourceType":135,"publicationDate":146,"lastChecked":18},"fda-direct-to-consumer-tests-2019","Direct-to-Consumer Tests","https://www.fda.gov/medical-devices/in-vitro-diagnostics/direct-consumer-tests","US Food and Drug Administration","2019-12-20",{"sourceId":148,"title":149,"canonicalId":150,"canonicalUrl":151,"publisher":152,"sourceType":153,"publicationDate":154,"lastChecked":18},"idsa-candidiasis-guideline-2016","Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America","DOI:10.1093/cid/civ933","https://www.idsociety.org/practice-guideline/candidiasis/","Infectious Diseases Society of America","guideline","2016-02-15",{"sourceId":156,"title":157,"canonicalId":158,"canonicalUrl":159,"publisher":160,"sourceType":153,"publicationDate":161,"lastChecked":18},"porcari-microbiome-testing-consensus-2025","International consensus statement on microbiome testing in clinical practice","doi:10.1016/S2468-1253(24)00311-X","https://pubmed.ncbi.nlm.nih.gov/39647502/","The Lancet Gastroenterology & Hepatology","2025-02-01",{"sourceId":163,"title":164,"canonicalId":165,"canonicalUrl":166,"publisher":134,"sourceType":153,"publicationDate":167,"lastChecked":18},"cdc-syphilis-herxheimer-2024","Syphilis — STI Treatment Guidelines: Jarisch-Herxheimer Reaction","doi:10.15585/mmwr.rr7004a1","https://www.cdc.gov/std/treatment-guidelines/syphilis.htm","2021-07-23",{"sourceId":169,"title":170,"canonicalId":171,"canonicalUrl":172,"publisher":173,"sourceType":174,"publicationDate":175,"lastChecked":18},"jaiswal-candida-dieoff-review-2024","Candida die-off: Adverse effect and neutralization with phytotherapy approaches","PMID:38072320; DOI:10.1016/j.toxicon.2023.107555","https://pubmed.ncbi.nlm.nih.gov/38072320/","Toxicon","other","2024-01-01",{"sourceId":177,"title":178,"canonicalId":179,"canonicalUrl":180,"publisher":181,"sourceType":135,"publicationDate":182,"lastChecked":18},"fda-dietary-supplements-2022","FDA 101: Dietary Supplements","FDA consumer update: FDA 101 Dietary Supplements","https://www.fda.gov/consumers/consumer-updates/fda-101-dietary-supplements","U.S. Food and Drug Administration","2022-06-02",{"sourceId":184,"title":185,"canonicalId":186,"canonicalUrl":187,"publisher":181,"sourceType":135,"publicationDate":182,"lastChecked":18},"fda-mixing-supplements-medications-2022","Mixing Medications and Dietary Supplements Can Endanger Your Health","FDA consumer update: mixing medications and dietary supplements","https://www.fda.gov/consumers/consumer-updates/mixing-medications-and-dietary-supplements-can-endanger-your-health",{"sourceId":189,"title":190,"canonicalId":191,"canonicalUrl":192,"publisher":181,"sourceType":135,"publicationDate":193,"lastChecked":18},"fda-supplement-problem-reporting-2025","How to Report a Problem with Dietary Supplements","FDA dietary-supplement adverse-event reporting page","https://www.fda.gov/food/dietary-supplements/how-report-problem-dietary-supplements","2025-03-13",{"sourceId":195,"title":196,"canonicalId":197,"canonicalUrl":198,"publisher":196,"sourceType":199,"publicationDate":200,"lastChecked":18},"988-lifeline-us-2022","988 Suicide & Crisis Lifeline","US three-digit crisis service 988","https://988lifeline.org/","official-care-service","2022-07-16",[202,246,258,270,283],{"claimId":203,"exactClaim":204,"outcome":205,"population":206,"verdict":207,"evidenceLevel":208,"rationale":209,"safetyStatus":210,"evidenceAsOf":18,"lastUpdated":18,"status":211,"changeHistory":212,"sources":213},"broad-candida-symptom-cluster-establishes-cause","A broad cluster of nonspecific symptoms such as fatigue, bloating, altered bowel habits, concentration difficulty, mood symptoms, cravings, or skin complaints establishes intestinal Candida overgrowth as their shared cause.","valid causal attribution of a nonspecific multisystem symptom cluster to intestinal Candida overgrowth","immunocompetent adolescents and adults with chronic gastrointestinal and/or extraintestinal symptoms but without established site-specific or invasive candidiasis","not-supported","moderate","A systematic review of 96 eligible citations found intestinal Candida colonization common in healthy immunocompetent adults and found neither epidemiologic nor therapeutic evidence for a Candida or Candida-hypersensitivity syndrome. Current CDC and IDSA disease definitions do not recognize a symptom-list diagnosis of systemic or intestinal candidiasis. The controlled nystatin trial in women meeting proposed candidiasis-hypersensitivity criteria found no meaningful advantage over placebo for systemic or psychological symptoms. Early SIFO studies concern a narrower, selected gastrointestinal population assessed by small-bowel aspirate and cannot validate a broad multisystem syndrome. Plausible alternatives depend on the symptom pattern and include functional gastrointestinal disorders, medication effects, dietary intolerance, endocrine or hematologic disease, dermatologic conditions, sleep or mood disorders, and other infections; the attribution should stop and pivot to evaluation of the actual symptoms when a recognized Candida condition has not been established.","usual-cautions","active",[],[214,221,222,225,226,233,240],{"title":215,"canonicalId":216,"canonicalUrl":217,"publisher":218,"sourceType":219,"publicationDate":220,"lastChecked":18},"The pathogenetic significance of intestinal Candida colonization: a systematic review from an interdisciplinary and environmental medical point of view","PMID:12068745; DOI:10.1078/1438-4639-00159","https://pubmed.ncbi.nlm.nih.gov/12068745/","International Journal of Hygiene and Environmental Health","systematic-review","2002-05-01",{"title":131,"canonicalId":132,"canonicalUrl":133,"publisher":134,"sourceType":135,"publicationDate":136,"lastChecked":18},{"title":223,"canonicalId":132,"canonicalUrl":224,"publisher":134,"sourceType":135,"publicationDate":136,"lastChecked":18},"Clinical Overview of Invasive Candidiasis","https://www.cdc.gov/candidiasis/hcp/clinical-overview/",{"title":149,"canonicalId":150,"canonicalUrl":151,"publisher":152,"sourceType":153,"publicationDate":154,"lastChecked":18},{"title":227,"canonicalId":228,"canonicalUrl":229,"publisher":230,"sourceType":231,"publicationDate":232,"lastChecked":18},"A randomized, double-blind trial of nystatin therapy for the candidiasis hypersensitivity syndrome","PMID:2247104; DOI:10.1056/NEJM199012203232501","https://pubmed.ncbi.nlm.nih.gov/2247104/","New England Journal of Medicine","randomized-trial","1990-12-20",{"title":234,"canonicalId":235,"canonicalUrl":236,"publisher":237,"sourceType":238,"publicationDate":239,"lastChecked":18},"Dysmotility and proton pump inhibitor use are independent risk factors for small intestinal bacterial and/or fungal overgrowth","PMID:23574267; DOI:10.1111/apt.12304","https://pubmed.ncbi.nlm.nih.gov/23574267/","Alimentary Pharmacology & Therapeutics","observational-study","2013-06-01",{"title":241,"canonicalId":242,"canonicalUrl":243,"publisher":244,"sourceType":174,"publicationDate":245,"lastChecked":18},"Small intestinal fungal overgrowth","PMID:25786900; DOI:10.1007/s11894-015-0436-2","https://pubmed.ncbi.nlm.nih.gov/25786900/","Current Gastroenterology Reports","2015-04-01",{"claimId":247,"exactClaim":248,"outcome":249,"population":250,"verdict":251,"evidenceLevel":252,"rationale":253,"safetyStatus":210,"evidenceAsOf":18,"lastUpdated":18,"status":211,"changeHistory":254,"sources":255},"candida-testing-requires-condition-specific-method","There is no single Candida test that establishes every form of candidiasis; a diagnostically useful method and sample must match the suspected body site or invasive-disease setting and be interpreted with the clinical findings.","valid diagnosis or exclusion of the specific suspected form of candidiasis","adolescents and adults being evaluated for possible vaginal, oral or throat, esophageal, or invasive candidiasis","supported","strong","Current CDC diagnostic guidance assigns different examinations, specimen sites, microscopy, culture, endoscopy, and blood or infected-site testing to different Candida conditions. IDSA likewise treats culture and nonculture assays as condition-dependent tools and requires assay limitations, invasive-disease type, risk, and clinical setting to be considered. A result can contribute to the defined diagnosis for which the test was validated; it cannot establish unrelated Candida explanations across body sites, and negative blood culture alone does not exclude every deep-seated invasive infection because sensitivity is limited.",[],[256,257],{"title":139,"canonicalId":132,"canonicalUrl":140,"publisher":134,"sourceType":135,"publicationDate":136,"lastChecked":18},{"title":149,"canonicalId":150,"canonicalUrl":151,"publisher":152,"sourceType":153,"publicationDate":154,"lastChecked":18},{"claimId":259,"exactClaim":260,"outcome":261,"population":262,"verdict":251,"evidenceLevel":208,"rationale":263,"safetyStatus":210,"evidenceAsOf":18,"lastUpdated":18,"status":211,"changeHistory":264,"sources":265},"candida-test-review-prepares-clinical-evaluation","Before buying or acting on a Candida-related test, reviewing its intended condition, specimen, analytical and clinical validation, applicable population, limitations, and how either result would change care is a constructive way to prepare for clinical evaluation.","informed test selection and interpretation without treating a result as a stand-alone diagnosis or treatment instruction","adolescents and adults with unresolved or chronic symptoms who are considering a home, direct-access, or clinician-ordered Candida-related test","FDA guidance asks consumers to discuss which tests may be useful, understand benefits and limitations, determine whether claims have analytical and clinical validity, and avoid making dietary or health decisions from a result alone. CDC shows that legitimate Candida testing begins with the suspected condition and relevant examination or specimen, while IDSA requires invasive assays to be interpreted in their clinical and risk context. The microbiome consensus adds pre-test clinical information and clinician-led management. A practical discussion can therefore bring the exact report and method, symptom pattern and timing, medications and prior treatments, relevant risk factors, and the question each possible result would answer; evaluation can then target the symptoms and recognized differentials rather than assume a broad Candida cause.",[],[266,267,268,269],{"title":143,"canonicalId":132,"canonicalUrl":144,"publisher":145,"sourceType":135,"publicationDate":146,"lastChecked":18},{"title":139,"canonicalId":132,"canonicalUrl":140,"publisher":134,"sourceType":135,"publicationDate":136,"lastChecked":18},{"title":149,"canonicalId":150,"canonicalUrl":151,"publisher":152,"sourceType":153,"publicationDate":154,"lastChecked":18},{"title":157,"canonicalId":158,"canonicalUrl":159,"publisher":160,"sourceType":153,"publicationDate":161,"lastChecked":18},{"claimId":271,"exactClaim":272,"outcome":273,"population":274,"verdict":207,"evidenceLevel":208,"rationale":275,"safetyStatus":276,"evidenceAsOf":18,"lastUpdated":18,"status":211,"changeHistory":277,"sources":278},"worsening-proves-candida-treatment-is-working","New, persistent, or worsening physical or psychological symptoms during an antifungal, supplement, cleanse, or restrictive diet prove that Candida is dying and the intervention is working, so the worsening should be endured or the intervention intensified.","validity of worsening as evidence of Candida treatment efficacy and as a reason to continue or intensify an intervention","adolescents and adults using prescription or non-prescription interventions for confirmed candidiasis or presumed broad Candida overgrowth who develop new, persistent, or worsening symptoms","Treatment effectiveness for defined candidiasis is assessed by the relevant clinical and microbiological outcome, not by nonspecific deterioration. CDC's defined Jarisch-Herxheimer guidance is limited to syphilis and cannot validate a Candida inference. The Candida die-off narrative review supplies no controlled evidence that worsening predicts fungal clearance or benefit. Worsening can overlap with an adverse reaction, progression, an incorrect diagnosis, nutritional or medication effects, or another condition and must never be normalized as proof of healing; exact observable triggers and actions remain locale-safety work.","elevated-risk",[],[279,280,281,282],{"title":164,"canonicalId":165,"canonicalUrl":166,"publisher":134,"sourceType":153,"publicationDate":167,"lastChecked":18},{"title":170,"canonicalId":171,"canonicalUrl":172,"publisher":173,"sourceType":174,"publicationDate":175,"lastChecked":18},{"title":149,"canonicalId":150,"canonicalUrl":151,"publisher":152,"sourceType":153,"publicationDate":154,"lastChecked":18},{"title":131,"canonicalId":132,"canonicalUrl":133,"publisher":134,"sourceType":135,"publicationDate":136,"lastChecked":18},{"claimId":284,"exactClaim":285,"outcome":286,"population":287,"verdict":288,"evidenceLevel":289,"rationale":290,"safetyStatus":210,"evidenceAsOf":18,"lastUpdated":18,"status":291,"changeHistory":292,"sources":293},"dieoff-label-alone-does-not-justify-crisis-routing","Using the label 'Candida die-off,' reporting treatment-related worsening, or participating in a die-off journey, without an observable disclosure or sign of acute psychological danger, is sufficient on its own to predict an acute crisis and trigger condition-specific crisis routing.","validity of the die-off label or worsening alone as a predictor and triage criterion for acute psychological crisis","adolescents and adults reporting Candida-attributed worsening during an antifungal, supplement, cleanse, or restrictive diet","not-enough-evidence","unclear","The reviewed die-off narrative includes psychological and physical worsening claims but provides no validated prognostic or triage evidence. Broader recurrent-urogenital literature documents group-level distress but does not validate a disease or journey label alone as a predictor of imminent harm. This boundary avoids a global alarm while preserving the importance of responding to an actual disclosure or observable sign; the exact locale trigger, care tier, resource, action, and expiry belong only to todos 055 and 056.","blocked",[],[294,295],{"title":170,"canonicalId":171,"canonicalUrl":172,"publisher":173,"sourceType":174,"publicationDate":175,"lastChecked":18},{"title":296,"canonicalId":297,"canonicalUrl":298,"publisher":299,"sourceType":174,"publicationDate":300,"lastChecked":18},"Psychosocial impact of recurrent urogenital infections: a review","doi:10.1177/17455057231216537","https://pubmed.ncbi.nlm.nih.gov/38099456/","SAGE Publications","2023-01-01",[302,316,329],{"safetyId":303,"observableTrigger":304,"careTier":305,"action":306,"applicablePopulations":307,"excludedPopulations":309,"locale":6,"checkedAt":18,"expiresAt":312,"sources":313},"us-candida-supplement-review-routine","Before starting a dietary supplement marketed for Candida, biofilms, die-off, gut health, or probiotic effects, the person takes a prescription or over-the-counter medicine, uses another supplement, is pregnant or breastfeeding, is a child, or has planned surgery or a recent change in health.","routine","Ask a physician, pharmacist, registered dietitian, or other qualified health professional to review the exact product label, full medicine and supplement list, health conditions, and planned surgery before use.",[308],"people in the United States considering an ingestible dietary supplement marketed for a Candida-related purpose who meet at least one listed trigger",[310,311],"people considering a conventional food rather than a dietary supplement","users with a serious reaction or acute crisis, who need the applicable faster route","2027-01-15",[314,315],{"title":178,"canonicalId":179,"canonicalUrl":180,"publisher":181,"sourceType":135,"publicationDate":182,"lastChecked":18},{"title":185,"canonicalId":186,"canonicalUrl":187,"publisher":181,"sourceType":135,"publicationDate":182,"lastChecked":18},{"safetyId":317,"observableTrigger":318,"careTier":319,"action":320,"applicablePopulations":321,"excludedPopulations":323,"locale":6,"checkedAt":18,"expiresAt":312,"sources":326},"us-candida-supplement-serious-reaction-prompt","While using a dietary supplement marketed for a Candida-related purpose, the person develops throat, lip, or tongue swelling; wheezing; fainting; chest pain; shortness of breath; severe persistent vomiting, diarrhea, or abdominal pain; blood in urine, stool, vomit, or sputum; yellow skin or eyes; or slurred speech, one-sided weakness, or sudden vision loss.","prompt","Stop using the supplement and seek immediate medical care; after immediate care is addressed, report the suspected reaction through the FDA Safety Reporting Portal.",[322],"people in the United States using an ingestible dietary supplement marketed for a Candida, biofilm, die-off, gut-health, or probiotic purpose who develop a listed serious reaction",[324,325],"people with mild self-limited symptoms not included in the FDA serious-reaction list","people not using a dietary supplement",[327,328],{"title":178,"canonicalId":179,"canonicalUrl":180,"publisher":181,"sourceType":135,"publicationDate":182,"lastChecked":18},{"title":190,"canonicalId":191,"canonicalUrl":192,"publisher":181,"sourceType":135,"publicationDate":193,"lastChecked":18},{"safetyId":330,"observableTrigger":331,"careTier":332,"action":333,"applicablePopulations":334,"excludedPopulations":336,"locale":6,"checkedAt":18,"expiresAt":338,"sources":339},"us-broad-candida-acute-crisis-emergency","A person describing Candida die-off or worsening during a Candida-labelled diet, supplement, probiotic, or antifungal says they are thinking about suicide, cannot stay safe, or are in acute emotional crisis.","emergency","Call or text 988, or use 988 Lifeline chat, now for free, confidential crisis support available 24 hours a day.",[335],"people in the United States who disclose the observable crisis trigger while discussing self-labelled Candida die-off or treatment-related worsening",[337],"people who use a die-off label or report worsening but do not disclose suicidal thoughts, inability to stay safe, or acute emotional crisis","2026-10-15",[340],{"title":196,"canonicalId":197,"canonicalUrl":198,"publisher":196,"sourceType":199,"publicationDate":200,"lastChecked":18},[342,345,348],{"rel":343,"hreflang":6,"href":344},"alternate","https://candipedia.org/en/tools/candida-claim-clinician-questions/",{"rel":343,"hreflang":346,"href":347},"pl-PL","https://candipedia.org/pl/narzedzia/pytania-do-lekarza-o-candide/",{"rel":343,"hreflang":349,"href":344},"x-default",1784685064873]